Cancer Family
Giant Cell Neoplasm
CI-CAN-00000020Explore in graph →
Non-malignant22 active trials3 evidence items
- NCIt
- C7069
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000020Explore in graph →
Clinical trials
158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05595603 | Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage | recruiting | Phase 2 | 153 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT01730950 | Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma | completed | Phase 2 | 182 | Radiation Therapy Oncology GroupNETWORK | 1 | Dec 29, 2022 |
| clinicaltrials |
| NCT00396279 | Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone | completed | Phase 2 | 37 | AmgenINDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT04952896 | Clinical Study of Magnetic Resonance Imaging and Deep Learning of Joint Synovial Disease | completed | — | 350 | Peking University Third HospitalOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT04255576 | Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone | unknown | Phase 1 / Phase 2 | 139 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Oct 14, 2022 | clinicaltrials |
| NCT00680992 | Study of Denosumab in Subjects With Giant Cell Tumor of Bone | completed | Phase 2 | 535 | AmgenINDUSTRY | 12 | Sep 22, 2022 | clinicaltrials |
| NCT04489420 | Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM(CYNK001GBM01) | terminated | Phase 1 | 3 | Celularity IncorporatedINDUSTRY | 1 | Aug 10, 2022 | clinicaltrials |
| NCT00731731 | Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 125 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2022 | clinicaltrials |
| NCT01609790 | Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | completed | Phase 2 | 137 | National Cancer Institute (NCI)NIH | 2 | Jul 21, 2022 | clinicaltrials |
| NCT05402865 | A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone | completed | — | 301 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Jun 2, 2022 | clinicaltrials |
| NCT02371369 | Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)(ENLIVEN) | completed | Phase 3 | 120 | Daiichi SankyoINDUSTRY | 12 | May 11, 2022 | clinicaltrials |
| NCT02015819 | Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas | completed | Phase 1 | 16 | City of Hope Medical CenterOTHER | 1 | Oct 20, 2021 | clinicaltrials |
| NCT02471716 | Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor(FPA008-002) | completed | Phase 1 / Phase 2 | 66 | Five Prime Therapeutics, Inc.INDUSTRY | 6 | Aug 31, 2021 | clinicaltrials |
| NCT01051557 | Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 / Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Jul 19, 2021 | clinicaltrials |
| NCT04955535 | Screening of Specific Genes for Pigmented Villous Nodular Synovitis | completed | — | 60 | Peking University Third HospitalOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT04002817 | Giant Cell Tumor of the Bone in Young Patients | completed | — | 18 | Istituto Ortopedico RizzoliOTHER | 1 | May 4, 2021 | clinicaltrials |
| NCT02255461 | Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors | terminated | Phase 1 | 35 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Mar 2, 2021 | clinicaltrials |
| NCT03620149 | Reduced Dose-density of Denosumab for Unresectable GCTB(REDUCE) | terminated | Phase 2 | 2 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Jan 6, 2021 | clinicaltrials |
| NCT01643850 | MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) | completed | Phase 2 | 36 | Novartis PharmaceuticalsINDUSTRY | 2 | Jan 5, 2021 | clinicaltrials |
| NCT00052208 | Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 158 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT03014804 | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT00943462 | Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM | withdrawn | — | 0 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 0 | Jul 23, 2020 | clinicaltrials |
| NCT01478321 | Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas | terminated | Phase 2 | 54 | Northwestern UniversityOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT01498328 | A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma(ReACT) | completed | Phase 2 | 127 | Celldex TherapeuticsINDUSTRY | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01514201 | Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2019 | clinicaltrials |
| NCT00423735 | Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 3 | Jul 24, 2019 | clinicaltrials |
| NCT02337426 | Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 | 12 | Virginia Commonwealth UniversityOTHER | 1 | Jun 28, 2019 | clinicaltrials |
| NCT00568906 | Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma | terminated | — | 129 | Stanford UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT00902577 | MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Apr 8, 2019 | clinicaltrials |
| NCT00464620 | Trial of Dasatinib in Advanced Sarcomas | completed | Phase 2 | 366 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Nov 23, 2018 | clinicaltrials |
| NCT01977677 | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | completed | Phase 1 / Phase 2 | 30 | Lawrence RechtOTHER | 1 | Oct 23, 2018 | clinicaltrials |
| NCT01804530 | Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors | terminated | Phase 1 | 59 | PlexxikonINDUSTRY | 1 | Aug 2, 2018 | clinicaltrials |
| NCT02673736 | A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor | terminated | Phase 1 | 11 | PlexxikonINDUSTRY | 1 | Aug 2, 2018 | clinicaltrials |
| NCT01103375 | Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma | terminated | Phase 1 | 5 | Wake Forest University Health SciencesOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT01575275 | Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme | terminated | Phase 2 | 8 | Michael Vogelbaum, MD, PhDOTHER | 1 | Jul 31, 2018 | clinicaltrials |
| NCT01836549 | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | terminated | Phase 2 | 43 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jul 20, 2018 | clinicaltrials |
| NCT01234805 | Yoga Therapy in Treating Patients With Malignant Brain Tumors | terminated | N/A | 9 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT00335764 | Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01648348 | Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 116 | National Cancer Institute (NCI)NIH | 1 | May 23, 2018 | clinicaltrials |
| NCT01234740 | Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases | completed | Phase 1 | 7 | City of Hope Medical CenterOTHER | 1 | Apr 17, 2018 | clinicaltrials |
| NCT00305864 | Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 118 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2018 | clinicaltrials |
| NCT01480479 | Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma(ACT IV) | completed | Phase 3 | 745 | Celldex TherapeuticsINDUSTRY | 24 | Jan 16, 2018 | clinicaltrials |
| NCT01753713 | Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma | completed | Phase 2 | 33 | Manmeet Ahluwalia, MDOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT03358212 | Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China | unknown | — | 100 | Peking University People's HospitalOTHER | 0 | Nov 30, 2017 | clinicaltrials |
| NCT01172964 | A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas | completed | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Nov 9, 2017 | clinicaltrials |
| NCT00045708 | A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2017 | clinicaltrials |
| NCT03259152 | Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone(D-Gct) | unknown | Phase 3 | 30 | Hebei Medical University Third HospitalOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00045110 | Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma | completed | Phase 1 / Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00980343 | GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Aug 16, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Mar 15, 2023source: clinicaltrials